• Measure Summary
  • NQMC:009763
  • 2012 May

Androgen deficiency: percentage of male patients aged 18 years and older with androgen deficiency who are receiving testosterone therapy, who have a baseline gonadotropin (LH or FSH) measurement performed within six months prior to initiating testosterone therapy.

The Endocrine Society

  • Measure Summary
  • NQMC:011054
  • 2017 Jun
  • NQF-Endorsed Measure

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer.

American Medical Association; American Urological Association

  • Measure Summary
  • NQMC:011155
  • 2016 Jun

Testicular cancer: proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin area under the curve of 7 mg/ml/min (AUC7), based on ethylene diamine tetra-acetic acid (EDTA) clearance, within 8 weeks of orchidectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011158
  • 2016 Jun

Testicular cancer: proportion of patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011210
  • 2016 Jul

Prostate cancer: proportion of patients with prostate cancer who are enrolled in an interventional clinical trial or translational research.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011199
  • 2016 Jul

Prostate cancer: proportion of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the multidisciplinary team (MDT) meeting before definitive treatment.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:010099
  • 2014 Nov

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy with documented evaluation of prostate-specific antigen (PSA), AND primary tumor (T) stage, AND Gleason score prior to initiation of treatment.

American Urological Association; Physician Consortium for Performance Improvement®

  • Measure Summary
  • NQMC:011196
  • 2016 Jul

Prostate cancer: proportion of patients with intermediate risk prostate cancer undergoing radical treatment who have MRI of the prostate.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011205
  • 2016 Jul

Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 0 pads per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011153
  • 2016 Jun

Testicular cancer: proportion of patients with testicular cancer who are discussed at a multidisciplinary team (MDT) meeting to agree on a definitive management plan post orchidectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:009971
  • 2014 Sep

Preventive services for adults: percentage of male patients ages 45 to 79 years at risk for myocardial infarctions who receive aspirin chemoprophylaxis counseling.

Institute for Clinical Systems Improvement

  • Measure Summary
  • NQMC:011208
  • 2016 Jul

Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo trans-rectal ultrasound guided (TRUS) prostate re-biopsy within 14 months of diagnosis.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011150
  • 2016 Jun

Testicular cancer: proportion of patients with testicular cancer who undergo CT scanning of the chest, abdomen and pelvis within 3 weeks of orchidectomy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:009977
  • 2014 Sep

Preventive services for adults: percentage of male patients age 35 years and older who have lipid screening every five years.

Institute for Clinical Systems Improvement

  • Measure Summary
  • NQMC:010102
  • 2014 Nov
  • NQF-Endorsed Measure

Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence, receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH agonist or antagonist).

American Urological Association; Physician Consortium for Performance Improvement®

  • Measure Summary
  • NQMC:011197
  • 2016 Jul

Prostate cancer: proportion of patients with high risk prostate cancer undergoing radical treatment who have MRI of the prostate and isotope bone scan (or alternative whole body MRI evaluation).

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011159
  • 2016 Jun

Testicular cancer: proportion of patients with testicular cancer who die within 30 days of treatment for testicular cancer.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:009764
  • 2012 May

Androgen deficiency: percentage of male patients aged 18 years and older with androgen deficiency who are receiving testosterone therapy, who have a hematocrit or hemoglobin test performed within two to six months after initiation of testosterone therapy.

The Endocrine Society

  • Measure Summary
  • NQMC:011156
  • 2016 Jun

Testicular cancer: proportion of patients with metastatic testicular cancer who have serum tumour markers (STMs) checked 2 weeks before starting chemotherapy.

NHS Scotland; Scottish Cancer Taskforce

  • Measure Summary
  • NQMC:011203
  • 2016 Jul

Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy.

NHS Scotland; Scottish Cancer Taskforce